Share This

Create Your Own Business Intelligence Website   Input the stock code or the company name     Search   <01349.HK> - SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO., LTD.    Stock Screener：Biotechnology, Biotechnology HUTCHMED INNOVATIVE PHAR UNI-BIO GROUP KING INTL INV BBI LIFE SCI ESSEX BIO-TECH JACOBIO-B CANBRIDGE-B 3D MEDICINES OCUMENSION-B FRONTAGE 3SBIO IMMUNEONCO-B GENSCRIPT BIO ASCLETIS-B INNOVENT BIO VIVA BIOTECH TOT BIOPHARM-B JUNSHI BIO EVEREST MED-B LAEKNA-B JW THERAP-B BRII-B HBM HOLDINGS-B LEPU BIO-B KEYMED BIO-B BASECARE-B CARSGEN-B RECBIO-B MABPHARM-B CLOVER BIO-B ABBISKO-B SIRNAOMICS-B WUXI XDC WUXI BIO BIOCYTOGEN-B MEILLEUREHEALTH WUXI APPTEC GIANT BIOGENE LUZHU BIOTECH-B CUTIA-B YZYBIO-B QYUNS-B HIGHTIDE-B HUA MEDICINE-B CSTONE PHARMA-B HENLIUS TIGERMED SINOMAB BIO-B CT ENTERPRISE AUSTAR JOINN BEIGENE CANSINOBIO SCICLONE PHARMA TRANSCENTA-B AIM VACCINE MEGA GENOMICS HAOHAI BIOTEC ASCENTAGE-B BOAN BIOTECH IMMUNOTECH-B SKB BIO-B ANTENGENE-B GENOR-B HAO WEN HLDGS HK LIFE SCI CRMI PFC DEVICE BIOSINO BIO-TEC NEP INTERLONG CORNERSTONE TEC HUAKANG BIOMED    Basic Datum Company name Lot P/E P/B EPS DPS FUDANZHANGJIANG 1000 21.15 0.8503 0.1206 0.0767 Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend    Related links    Related news   ≫More    Company Rating Date Broker Company name Rating Target ≫More    Company performance - Published Date Company name Turnover* Profit* % Dividend ≫More    Comment 2013-12-30　復旦張江（1349）今年股價累飆逾1.7倍，預測市盈率超過40倍。今年首九個月盈利按年增72%至5,400萬元人民幣。公司研製的皮膚病和腫瘤的核心藥物市場競爭能力強，面對的競爭較少，旗下藥品不納入醫保範圍之內，故沒有直接受到藥價下降壓力。      Top Gain / Loss Show All Charts     Value Name Updated Value Change Change % HSI 04-23 09:30 16682.7 ▲ 171 ▲ 1.04% FUDANZHANGJIANG 04-25 15:55 2.12 ▲ 2.12 ▲ ∞% ≫More

Mobile | Full

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map

Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved

Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.